{"disease":{"id":"respiratory-tract-neoplasm","name":"respiratory tract neoplasm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05337163","title":"A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China","phase":"","overall_status":"COMPLETED","enrollment_count":1564,"lead_sponsor_name":"Creative Biosciences (Guangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT06494241","title":"Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06376084","title":"Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":532,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03134872","title":"A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":419,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT04697446","title":"External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":279,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT04222972","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":223,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04862780","title":"(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03085069","title":"A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":146,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT03389256","title":"Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":144,"lead_sponsor_name":"Sichuan Cancer Hospital and Research Institute","has_results":false},{"nct_id":"NCT05241873","title":"(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":103,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03868579","title":"Rapid On Site Evaluation of Pleural Touch Preparations in Diagnosing Malignant Pleural Effusion in Patients Undergoing Pleuroscopy","phase":"NA","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07247786","title":"Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":68,"lead_sponsor_name":"Fundación GECP","has_results":false},{"nct_id":"NCT06917573","title":"PALACE: Cemiplimab Trial According to ctDNA Levels","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":63,"lead_sponsor_name":"Fundación GECP","has_results":false},{"nct_id":"NCT06177925","title":"A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT03093909","title":"Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04776447","title":"Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":38,"lead_sponsor_name":"Fundación GECP","has_results":false},{"nct_id":"NCT07242547","title":"Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Fundación GECP","has_results":false},{"nct_id":"NCT03422302","title":"Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02909452","title":"Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT02897778","title":"Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT05797246","title":"Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05153408","title":"(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT04371796","title":"Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Sichuan Cancer Hospital and Research Institute","has_results":false},{"nct_id":"NCT04644315","title":"A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06841874","title":"Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false}],"total":27},"guidelines":[],"source":"Drug Landscape verified database"}